Proteinuria. Skeletal muscle effects eg, myalgia, myopathy & rarely, rhabdomyolysis. Clinical monitoring of creatinine kinase levels monitoring is recommended. Discontinue therapy if CK levels are markedly elevated (>5 x ULN). Not to be co-administered w/ systemic formulations of fusidic acid or w/in 7 days of stopping fusidic acid treatment. Not to be used in patients w/ acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis. Patients who consume excessive quantities of alcohol &/or have history of liver disease. Carry out liver function tests prior to & 3 mth following the initiation of treatment. Discontinue or reduce dose if the level of serum transaminases is >3 x ULN. Patients w/ secondary hypercholesterolemia caused by hypothyroidism or nephrotic syndrome. Concomitant use w/ PIs. Interstitial lung disease. DM. May affect ability to drive or operate machinery. Women of childbearing potential. Childn <6 yr. Asians.